Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GRCE

Grace Therapeutics

GRCE Lead: NDA Submitted 7 Biotech Distilled articles ↓ 20 filings & releases ↓ Cash $13.8M (Jun 30, 2026) ↓ 7 verdicts ↓
Neurology Small Molecule

Market cap $38.9M 21.0M shares (10-Q, Aug 11, 2026) × $1.85 close Nov 6, 2026

Most recent annual filing: 2026-06-18

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. GRCE resubmission manufacturing pathway filinglate 2027GRCE resubmission manufacturing pathway filing, late 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Discontinued (2)

Capital (as filed)

Cash
$13.8M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$3.2M quarter to Jun 30, 2026 (10-Q)
As stated in coverage
$17.0M cash, runway end of calendar 2028 per the update of Aug 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Grace Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-26 Buy core Grace Therapeutics (GRCE): Scientific Deep Dive for GTx-104 and Pipeline Products The combination of strong PK data (scientific de-risking) and the January 10 8-K severance amendments (governance signaling) tilts probability heavily toward an approval-then-buyout scenario on the April 2026 PDUFA date.
  2. 2026-02-14 Speculative buy speculative UPDATE: Grace Therapeutics (GRCE) – The Float Shrinks as the Smart Money Parks for PDUFA M&A arbitrage thesis strengthens as institutional smart money locks up ~16% of the float and financials confirm full runway through the April PDUFA date, though CMC risk remains.
  3. 2026-04-24 Avoid UPDATE: Grace Therapeutics (GRCE) - The Silent Killer Strikes: Grace Gets a CRL The FDA issued a CRL based entirely on CMC and manufacturing deficiencies, triggering the pre-stated stop-loss and killing the M&A arbitrage thesis as a dilutive raise now appears inevitable.
  4. 2026-04-28 Watch UPDATE: Grace Therapeutics (GRCE) - The CRL Autopsy and the Smart Money Exit SELL is maintained while a potential re-entry watch list forms post-financing, as AIGH trims below 5%, the CDMO may need to be swapped, and a dilutive raise at or below $2 appears imminent.
  5. 2026-06-18 Watch UPDATE: Grace Therapeutics (GRCE) - The Pipeline Gets Euthanized and the Auditor Rings the Bell SELL maintained as pipeline is formally written off ($13.5M impairment), KPMG flags going-concern as a Critical Audit Matter, and CDMO remediation path remains unresolved — dilutive raise still the next real event.
  6. 2026-07-28 Watch UPDATE: Grace Therapeutics (GRCE) - The Type A Answer: Two Factories, No Date Upgraded from SELL to WATCH as the Type A meeting confirms a dual-source CDMO strategy and retires the worst-case CMC scenario, but no resubmission date and the dilutive raise remains the next gating event.
  7. 2026-08-06 Speculative buy speculative UPDATE: Grace Therapeutics (GRCE) - The Raise Prints at $2.10 The gating dilution event has printed at-the-market with no warrants, extending runway to end-2028 and covering the dual-CDMO remediation, making a small sized-to-lose entry defensible for the first time since the CRL.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)